Overview of the treatment of myasthenia gravis market - Avoidance of drugs that may exacerbate myasthenia | Causes, Symptoms, and Diagnosis by 2027
Global Myasthenia Gravis Treatment Market Analysis
Overview
Myasthenia gravis (MG) is an inflammatory neuromuscular disease that causes muscle tissue fatigue in the arms and legs. Myasthenia gravis causes double vision, facial paralysis, trouble walking, and eyelid drooping. Tests such as repeated nerve stimulation, blood tests for toxins, edrophonium tests, computed tomography (CT) scans, and magnetic resonance imaging (MRI) are used to detect this condition. MG is treated with corticosteroids (cyclosporine and azathioprine) and acetylcholine esterase inhibitors (Pyridostigmine and Edrophonium).
Get Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/2625
Drivers
The global myasthenia gravis treatments market is expected to expand due to consistent research and development efforts. The US Food and Drug Administration approved Alexion Pharmaceuticals, Inc.'s Soliris, which contains eculizumab as an active ingredient, in October 2017. This medication is used to treat antibiotic generalized myasthenia gravis, as well as paroxysmal nocturnal hemoglobinuria (PNH), and atypical hemolytic uremic syndrome (aHUS).
Furthermore, the global myasthenia gravis treatments market is expected to increase as the number of clinical trials for the treatment of myasthenia gravis grows. Novartis AG began a phase II clinical trial of CFZ533 for the treatment of extreme myasthenia gravis in December 2017. The key role of CFZ533 is to deactivate white blood cells, which modifies the immune response. As a result, it can aid in the improvement and maintenance of serious myasthenia gravis.
ARGX-113 is now being studied in a therapeutic phase III trial by Argenx BVBA for the treatment of generalized myasthenia gravis. The drug ARGX-113, also known as Efgartigimod, is given intravenously. The research began in March 2019 and will be completed in June 2021.
Tailored Information as per niche requirement:
LIMITED TIME OFFER - Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/2625
Restraints
The global myasthenia gravis treatments market is projected to be hampered by side effects from the medications used to cure the disease. As per a study published in April 2019 by BioNews Services, LLC, high dose combinations of cholinesterase inhibitors (ChEIs) and calcineurine inhibitors (CNIs) including Mestinon and Prograf are to blame for extreme muscle cramps in myasthenia gravis patients. As a result, this aspect is expected to stifle growth of the global myasthenia gravis treatments market.
Regional Insights
Over the forecast period, North America is estimated to maintain its dominance in the global myasthenia gravis treatment market. This is due to the rising prevalence and occurrence of myasthenia gravis in the U.S. As per the National Center for Biotechnology Information (NCBI), the frequency of myasthenia gravis in the U.S. was about 5 to 30 cases per million individual years in October 2018, and the occurrence was about 10 to 20 cases per 100,000 individuals.
Moreover, due to increased research and development activities for myasthenia gravis treatment, Asia Pacific is expected to see substantial growth in the global myasthenia gravis treatment market. A phase III clinical trial of Azathioprine and Leflunomide for the treatment of myasthenia gravis is being conducted at Sun Yat-Sen University in China. The research began in September 2012 and is expected to be completed by January 2020.
To get detailed table of content (ToC), please click: https://www.coherentmarketinsights.com/ongoing-insight/toc/2625
Competitive Landscape
Major companies contributing in the global myasthenia gravis treatment market include Alexion Pharmaceutical Inc., CSL Behring, Grifols, S.A., Takeda Pharmaceutical Company Limited, Novartis AG, Avadel Pharmaceutical, PLC., Shire plc, Valeant Pharmaceutical International, Inc., Baxter International, Inc., and F. Hoffmann-La Roche AG.
Table of Content
Global Myasthenia Gravis Treatment Market Research Report
Section 1: Global Myasthenia Gravis Treatment Industry Overview
Section 2: Global Economic Impact on Myasthenia Gravis Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Myasthenia Gravis Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Myasthenia Gravis Treatment Market Forecast
Have a Look at Related Research Insights:
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- Coherent Market Insights
-
Name:
- Nirav Gokani
- Email:
-
Telephone:
- +918849480752
- Website:
Related Links
- Website: Myasthenia Gravis Treatment Market
